Structured Resource Names
Stable, versioned addresses that still resolve in ten years.
urn:osa:antibodies.example.org:ab:AB-04412@3Most scientific data outlives neither its grant nor its hard drive. We build archives that validate every deposit, version every record, and answer to people and machines. Open infrastructure, designed to outlast its builders.
To open an archive, request access.
The PDB works because deposition is structured, validation is thorough, and every record is addressable. Building that infrastructure takes years and a consortium.
A DOI on a ZIP is not a queryable dataset. Reuse depends on guessing what the columns mean.
Without validation at deposition, missing metadata and broken ontology terms surface years later, in someone else's analysis.
Training on public data means months of scraping and normalising, with no record of what was processed by which version of which script.
Someone has to keep the server up after the postdoc leaves. Many portals degrade within three years.
Open Science Archive is an open source scientific data platform: deposition, validation, records, search and export. Amacrin hosts OSA archives, so you can run a data bank for your field without operating one.
Nothing about your archive is proprietary. Export everything at any time, or take the node in-house and run it yourself.
Record schemas, validation checks, feature hooks. From that one file Amacrin derives the rest: deposition, builds, hosting, search and APIs.
Stable, versioned addresses that still resolve in ten years.
urn:osa:antibodies.example.org:ab:AB-04412@3Public reads by default. You decide who deposits and who curates.
antibodies.example.orgCompute, database, registry and TLS are ours to keep up. Export everything whenever you want.
tls · backups · upgradesEvery archive speaks MCP and publishes a skill file describing what it holds. Ask in plain language; answers come back as charts and tables, not raw JSON.
semantic search · typed filters · exports pinned to a build
Which VH germlines give the tightest PD-1 binders?
IGHV3-23 has the lowest median KD, but 68% of those entries are bivalent IgG measured by SPR, where avidity inflates apparent affinity. Restricted to monovalent Fab, the ranking flattens and IGHV1-69 comes out ahead. Germline explains little here: CDR-H3 length and composition carry most of the signal.
Most work on an archive starts by narrowing it: the records that pass QC, the assays from one platform, everything since the last release. A cut is that subset, exported with its features computed and given a name that resolves to exactly these rows.
amacrin cut antibodies \ --schema antibody-sequence@2.1.0 \ --where 'target = "PD-1" and qc.status = "pass"' \ --features affinity_kd_nM, expression_yield, embedding \ --format parquet
Query typed metadata. If a field is in the schema you can filter on it, and everything that matched passed the same checks.
Embeddings, QC metrics and predictions come out as columns, versioned with the build that produced them. Feed a model without rebuilding a pipeline.
Publish a cut as the official release and every member works from the same rows. Re-cut later and diff what changed.
Open any row and the record behind it answers: the specimen, the lab, the instrument, the licence, and everything that changed since.
The data model is the contract between member sites, and every contribution stays attributed.
The archive you were going to build in-house, with validation your funders can point to.
Agree the model before the contract starts and every CRO batch arrives validated and queryable.
Write the data model once; every future deposit inherits validation, search and a permanent address.
We're onboarding archives one field at a time. Leave your email and what you'd deposit, and we'll work with you to plan and set up your archive.
Running a consortium or a large release? Talk to us directly.